Business Context and Reporting Period
This Form 8-K Current Report was filed by Cerulean Pharma Inc. on June 26, 2015. The filing reports on corporate governance changes and the results of the Annual Meeting of Stockholders held on the same date. Note: The request metadata references "Dare Bioscience, Inc.," but the filing text explicitly identifies the registrant as Cerulean Pharma Inc.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance and stockholder voting results.
Material Changes
Board of Directors Changes
- Resignations: Ram Sasisekharan and Robert I. Tepper resigned as directors, effective June 26, 2015.
- Appointments: The Board size increased from eight to nine. Stuart A. Arbuckle was appointed as a new independent director, effective immediately. He joins the Audit Committee and the Nominating and Corporate Governance Committee.
- Stockholder Elections: Christopher D. T. Guiffre and Susan L. Kelley were elected as Class I directors to serve until the 2018 Annual Meeting.
Director Compensation Policy Amendments
The Board approved amendments to the non-employee director compensation policy, effective immediately for equity and July 1, 2015, for cash:
- Cash Retainer: $35,000 annually per director.
- Committee Fees: Audit ($7,500/$15,000 for chair), Compensation ($5,000/$10,000 for chair), Nominating/Governance ($3,500/$7,000 for chair), and Clinical Advisory ($10,000/$20,000 for chair).
- Equity Grants: Annual option to purchase 11,000 shares for directors serving six months; one-time option to purchase 22,000 shares for new directors.
- New Director Grant: Mr. Arbuckle received a one-time option to purchase 22,000 shares at an exercise price of $4.78 per share, vesting over three years.
Stockholder Voting Results
| Matter | Votes For | Votes Against | Votes Abstaining | Broker Non-Votes |
|---|---|---|---|---|
| Election of Christopher D. T. Guiffre | 18,028,934 | 5,800 | 8,940 | 4,793,377 |
| Election of Susan L. Kelley | 17,795,434 | 5,800 | 242,440 | 4,793,377 |
| Ratification of Deloitte & Touche LLP | 22,770,153 | 6,319 | 60,579 | 0 |
Guidance, Outlook, and Risks
The filing text does not contain financial guidance, operational outlook, management commentary on business performance, or specific risk factors. The document is limited to reporting the resignation of directors, the appointment of a new director, compensation policy changes, and the ratification of the independent auditor.
Key Facts for Investor Verification
- Verify the identity of the registrant: The filing is for Cerulean Pharma Inc., not Dare Bioscience, Inc.
- Confirm the new director's background: Stuart A. Arbuckle brings commercial leadership experience from Vertex Pharmaceuticals and Amgen.
- Review the updated director compensation structure, specifically the increase in cash retainers and the specific vesting schedules for equity grants.
- Note the significant number of broker non-votes (approx. 4.8 million) regarding the election of directors, indicating shares held by brokers where voting instructions were not received.
- Confirm the exercise price of the new director's stock option ($4.78) against the market price on June 26, 2015.